picture


Global market

  • 50 milion people in the world and 3 million people in Europe are affected by inflammatory bowel disease (IBD), which has a direct healthcare cost of 4.6 to 5.6 billion euros per year.
  • Diagnosis of IBD such as Crohn’s disease and ulcerative colitis tends to be slow and based on vague clinical parameters.
  • In addition to IBD, irritable bowel syndrome (IBS) is one of the 10 most difficult diseases to identify according to Fleming’s list.
  • It is estimated that up to 45% of patients wait more than one year for a diagnosis for these pathologies, whilst up to 17% wait more than five years. 

Our proposal

IBD and IBS are characterised by intermittent periods of flare-ups and no activity or remission, complicating follow-up with aggressive treatment and invasive techniques.

Thanks to our disruptive RAID-CD, an efficient, rapid and non-invasive diagnosis can be carried out by way of a stool test with high sensitivity and specificity to distinguish between Crohn’s disease, ulcerative colitis and irritable bowel syndrome, without the need for a colonoscopy.

Treatment prediction: microbiological balance can determine response to therapeutic approach such as anti-TNF treatment or post-surgery relapse in Crohn’s disease patient. Through the specific bacterial signature of RAID-CD we are able to determine its response before patient start treatment what helps to efficiently deal with therapeutic pauta.

RAID-CD will significantly improve the quality of life of patients.